Background: Propanidid is a γ-aminobutyric acid type A (GABAA) receptor agonist general anesthetic and its primary metabolite is 4-(2-[diethylamino]-2-oxoethoxy)-3-methoxy-benzeneacetic acid (DOMBA). Despite having a high water solubility at physiologic pH that might predict low-affinity GABAA receptor interactions, DOMBA is reported to have no effect on GABAA receptor currents, possibly because the DOMBA concentrations studied were simply insufficient to modulate GABAA receptors. Our objectives were to measure the propanidid and DOMBA concentration responses on -GABAA receptors and to measure the behavioral responses of DOMBA in mice at concentrations that affect GABAA receptor currents in vitro. Methods: GABAA receptors were expressed in oocytes using clones for the human GABAA α1, β2 and γ2s subunits. The effects of DOMBA (0.2–10 mmol/L) and propanidid (0.001–1 mmol/L) on oocyte GABAA currents were studied using standard 2-electrode voltage clamp techniques. Based on in vitro results, 6 mice received -DOMBA 32 mg intraperitoneal and were observed for occurrence of neurologic effects and DOMBA plasma concentration was measured by liquid chromatography tandem mass spectrometry. Results: DOMBA both directly activates GABAA receptors and antagonizes its GABA-mediated opening in a concentration-dependent manner at concentrations between 5–10 and 0.5–10 mmol/L respectively. In vivo, DOMBA produced rapid onset sedation at plasma concentrations that correlate with direct GABAA receptor activation. Conclusion: DOMBA modulation of GABAA receptors is associated with sedation in mice. Metabolites of propanidid analogues currently in development may similarly modulate GABAA, and impaired elimination of these metabolites could produce clinically relevant neurophysiologic effects.

Keywords:
GABAA receptor, DOMBA, Propanidid
1.
Doenicke A: General pharmacology of propanidid. Acta Anaesthesiol Scand Suppl 1965; 17: 21–26.
2.
Glen JB, Hunter SC: Pharmacology of an emulsion formulation of ICI 35 868. Br J Anaesth 1984; 56: 617–626.
3.
Habazettl H, Vollmar B, Rohrich F, Conzen P, Doenicke A, Baethmann A: [Anesthesiologic efficacy of propanidid as a liposome dispersion. An experimental study with rats]. Anaesthesist 1992; 41: 448–456.
4.
Buchwald P, Bodor N: Recent advances in the design and development of soft drugs. Pharmazie 2014; 69: 403–413.
5.
Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, Cook DR, Steffensen SC, Beattie DT: Azd-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology 2012; 116: 1267–1277.
6.
Wang S, Liu Q, Li X, Zhao X, Qiu L, Lin J: Possible binding sites and interactions of propanidid and AZD3043 within the γ-aminobutyric acid type a receptor (GABAAR). J Biomol Struct Dyn 2017: 1–12.
7.
Kalman S, Koch P, Ahlen K, Kanes SJ, Barassin S, Bjornsson MA, Norberg A: First human study of the investigational sedative and anesthetic drug azd3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers. Anesth Analg 2015; 121: 885–893.
8.
Norberg A, Koch P, Kanes SJ, Bjornsson MA, Barassin S, Ahlen K, Kalman S: A bolus and bolus followed by infusion study of azd3043, an investigational intravenous drug for sedation and anesthesia: safety and pharmacodynamics in healthy male and female volunteers. Anesth Analg 2015; 121: 894–903.
9.
Brosnan RJ, Pham TL: GABAA receptor modulation by phenyl ring compounds is associated with a water solubility cut-off value. Pharmacology 2016; 98: 13–19.
10.
Brosnan RJ, Pham TL: Hydrocarbon molar water solubility predicts NMDA vs. GABAA receptor modulation. BMC Pharmacol Toxicol 2014; 15: 62.
11.
Somogyi P, Fritschy JM, Benke D, Roberts JD, Sieghart W: The gamma 2 subunit of the GABAA receptor is concentrated in synaptic junctions containing the alpha 1 and beta 2/3 subunits in hippocampus, cerebellum and globus pallidus. Neuropharmacology 1996; 35: 1425–1444.
12.
Benke D, Mertens S, Trzeciak A, Gillessen D, Mohler H: GABAA receptors display association of gamma 2-subunit with alpha 1- and beta 2/3-subunits. J Biol Chem 1991; 266: 4478–4483.
13.
Mihic SJ, McQuilkin SJ, Eger EI 2nd, Ionescu P, Harris RA: Potentiation of gamma-aminobutyric acid type A receptor-mediated chloride currents by novel halogenated compounds correlates with their abilities to induce general anesthesia. Mol Pharmacol 1994; 46: 851–857.
14.
Vendramin Pasquetti M, Meier L, Loureiro S, Ganzella M, Junges B, Barbieri Caus L, Umpierrez Amaral A, Koeller DM, Goodman S, Woontner M, Gomes de Souza DO, Wajner M, Calcagnotto ME: Impairment of GABA ergic system contributes to epileptogenesis in glutaric acidemia type I. Epilepsia 2017.
15.
Hoke JF, Shlugman D, Dershwitz M, Michalowski P, Malthouse-Dufore S, Connors PM, Martel D, Rosow CE, Muir KT, Rubin N, Glass PS: Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology 1997; 87: 533–541.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.